

For Immediate Release**TSX Symbol: RVX****Dr. George Adams Joins Resverlogix Scientific Advisory Board**

CALGARY, AB, May 5, 2006 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX), announced today that Dr. George Adams, has joined the Scientific Advisory Board. Dr. Adams will help provide strategic consultation for the company’s development in its emerging cardiovascular program for drug eluting technologies, ReVas™.

Dr. George Adams, an expert in thrombosis and vascular biology, has partnered with Baxter Healthcare, World Heart, Dupont, Corvita, Pfizer and Boston Scientific over the last 30 years to develop and commercialize medical devices. Dr. Adams obtained his PhD. from McMaster University and has 124 publications including 9 invited reviews, 26 full papers and 3 patents. He is a past President of the Canadian Biomaterials Society. He is a reviewer for numerous scientific journals, national granting agencies and several national and provincial Centres of Excellence. He has been a principal investigator for over \$40 million in private and publicly-funded research and development.

“We are extremely pleased to add a leading authority in drug eluting technology such as Dr. Adams to our Scientific Advisory Board” stated Dr. Norman Wong, Co Founder and Chair of the Scientific Advisory Board at Resverlogix. “George’s in-depth knowledge of drug elution technology and its role in cardiovascular therapy will help provide important input in moving the ReVas™ technology program forward,” added Dr. Wong.

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix’s lead technology NexVas™, applies advanced medical research to develop therapies that increase ApoA-I the key protein of high density lipoprotein (HDL), the “good cholesterol,” and other targets to treat cardiovascular diseases (CVD). The Company’s second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Suite 202

279 Midpark Way SE

Calgary AB T2X 1M1

P 403.254.9252

F 403.256.8495

info@resverlogix.com

Donald J. McCaffrey
President/CEO
Resverlogix Corp.
Phone: 403-254-9252 ext. 223
Fax: 403-256-8495
Email: don@resverlogix.com

Kenneth Lebioda
Vice President Business Development
Resverlogix Corp.
Phone: 403-254-9252 ext. 227
Fax: 403-256-8495
Email: ken@resverlogix.com